The grant is expected to provide approximately US$3.6 million over three years to support the Phase 1 clinical development of the company’s lead molecule, KNX100, to treat symptoms associated with withdrawal in patients with opioid use disorder.
Kinoxis Therapeutics secures US government grant to progress drug development
June 7, 2023 Australian BiotechLatest Video
New Stories
-
Gilead announces eight recipients of inaugural Community Grants Program
March 28, 2024 - - Latest News -
Groups call for a new approach to reviewing and funding cancer medicines
March 28, 2024 - - Latest News -
Auditor General extends time to contribute to PBS performance audit
March 28, 2024 - - Latest News -
Reform bill redefines political donation and could exclude the industry from participating
March 27, 2024 - - Latest News -
NZ Government delivers funding boost for patients travelling to health treatment
March 27, 2024 - - Latest News -
Clarity Pharmaceuticals launches $121 million fully underwritten equity raising
March 26, 2024 - - Australian Biotech -
More states announce RSV programs as families call for national action
March 26, 2024 - - Latest News